Literature DB >> 1808814

Advanced Coats' disease.

B G Haik.   

Abstract

Advanced Coats' disease and retinoblastoma can both present with the triad of a retinal detachment, the appearance of a subretinal mass, and dilated retinal vessels. Thus, even the most experienced observer may not be able to differentiate these entities on ophthalmoscopic findings alone. Coats' disease is the most common reason for which eyes are enucleated with the misdiagnosis of retinoblastoma. Ultrasonography is the auxiliary diagnostic test most easily incorporated into the clinical examination, and can be utilized repeatedly without biologic tissue hazard. Ultrasonically identifiable features allowing differentiation between Coats' disease and retinoblastoma include the topography and character of retinal detachment and presence or absence of subretinal calcifications. Ultrasonography is of lesser use in poorly calcified retinoblastoma and in detecting optic nerve or extraocular extension in heavily calcified retinoblastoma. CT is perhaps the single most valuable test because of its ability to: (a) delineate intraocular morphology, (b) quantify subretinal densities, (c) identify vascularities within the subretinal space through the use of contrast enhancement, and (d) detected associated orbital or intracranial abnormalities. Optimal computed tomographic studies, however, require multiple thin slices both before and after contrast introduction and expose the child to low levels of radiation if studies are repeated periodically. MR imaging is valuable for its multiplanar imaging capabilities, its superior contrast resolution, and its ability to provide insights into the biochemical structure and composition of tissues. It is limited in its ability to detect calcium, which is the mainstay of ultrasonic and CT differentiation. Aqueous LDH and isoenzyme levels were not valuable in distinguishing between Coats' disease and retinoblastoma. The value of aqueous NSE levels in the differentiation of advanced Coats' disease and exophytic retinoblastoma deserves further study. Specimens from patients with intraocular hemorrhage should be viewed cautiously, since erythrocytes contain high levels of enolase. Analysis of subretinal aspirates is an extremely accurate method of confirming the diagnosis of Coats' disease. The key diagnostic findings are the presence of cholesterol crystals and pigment-laden macrophages and the absence of tumor cells on fresh preparations. The technique should be reserved for patients where retinoblastoma has been ruled out by all noninvasive means and massive subretinal drainage is anticipated. The natural progression in advanced Coats' disease is toward the development of a blind, painful eye. Spontaneous regression does rarely occur, and some eyes quietly progress to a phthisical state.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1808814      PMCID: PMC1298633     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  106 in total

1.  Coats' disease in a renal transplant recipient.

Authors:  M Berger; K V Lieberman; M J Schoeneman; J S Schuman; A H Friedman
Journal:  Nephrol Dial Transplant       Date:  1987       Impact factor: 5.992

2.  Natural history and management of advanced Coats' disease.

Authors:  S W Silodor; J J Augsburger; J A Shields; W Tasman
Journal:  Ophthalmic Surg       Date:  1988-02

Review 3.  The radiologic evaluation of congenital and pediatric lesions of the orbit.

Authors:  K D Hopper; D K Haas; J L Sherman
Journal:  Semin Ultrasound CT MR       Date:  1988-12       Impact factor: 1.875

4.  Cytologic and biochemical examination of the subretinal fluid in diagnosis of Coats' disease.

Authors:  I Kremer; I Nissenkorn; I Ben-Sira
Journal:  Acta Ophthalmol (Copenh)       Date:  1989-06

5.  Calcifications in Coats' disease.

Authors:  J Pe'er
Journal:  Am J Ophthalmol       Date:  1988-12-15       Impact factor: 5.258

6.  A case of retinitis pigmentosa associated with Coats' syndrome.

Authors:  M Yuguchi; A Majima
Journal:  Ophthalmic Paediatr Genet       Date:  1984-12

7.  Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course.

Authors:  P M Zeltzer; P J Marangos; A E Evans; S L Schneider
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

8.  Neuron-specific enolase and retinoblastoma. Clinicopathologic correlations.

Authors:  D H Abramson; D S Greenfield; R M Ellsworth; M Fleisher; R Weiss; B Haik; M K Schwartz; R Bhalla
Journal:  Retina       Date:  1989       Impact factor: 4.256

9.  Exudative retinitis pigmentosa.

Authors:  A Spallone
Journal:  Ophthalmologica       Date:  1988       Impact factor: 3.250

Review 10.  Coats'-type retinitis pigmentosa.

Authors:  J A Khan; C H Ide; M P Strickland
Journal:  Surv Ophthalmol       Date:  1988 Mar-Apr       Impact factor: 6.048

View more
  6 in total

1.  Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.

Authors:  Michael R R Böhm; Constantin E Uhlig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-12       Impact factor: 3.117

2.  Uveal Melanoma Mimicking Advanced Coats' Disease in a Young Patient.

Authors:  Naina Gupta; William Terrell; Lynn Schoenfield; Claudia Kirsch; Colleen M Cebulla
Journal:  Ocul Oncol Pathol       Date:  2015-11-20

Review 3.  Paediatric retinal detachment: a review.

Authors:  Raffaele Nuzzi; Carlo Lavia; Roberta Spinetta
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

4.  Vasoproliferative tumours of the retina.

Authors:  H Heimann; N Bornfeld; O Vij; S E Coupland; N E Bechrakis; U Kellner; M H Foerster
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

5.  Coats' disease: an Indian perspective.

Authors:  Pukhraj Rishi; Ekta Rishi; Mahesh Uparkar; Tarun Sharma; Lingam Gopal; Pramod Bhende; Muna Bhende; Pratik Ranjan Sen; Parveen Sen
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

6.  Coats' disease: characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease.

Authors:  Yacoub A Yousef; Ahmad H ElRimawi; Rashed M Nazzal; Ahmad F Qaroot; Adnan H AlAref; Mona Mohammad; Omar Abureesh; Robert Rejdak; Katarzyna Nowomiejska; Teresio Avitabile; Mario Damiano Toro; Ibrahim AlNawaiseh
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.